Macomics bags £4.24m (US$5.92m) as it aims to accelerate macrophage-based therapeutics portfolio

UK – Macomics, a UK immuno-oncology company, has raised £4.24m in follow-on financing from its 2020 seed round as it aims to accelerate the development of its macrophage-based therapeutics portfolio. The new investment and planned Series A financing will enable Macomics to accelerate progress if its antibody programmes toward the clinics while also expanding its portfolio and further investing in its target discovery technology. Its target discovery platform will enable the identification and validation of novel macrophage therapeutic targets, based on a ‘deep understanding of macrophage biology’. The company also…

Read More